DeepCure discovers transformative small molecule therapies for immune and inflammatory diseases. The company uses a chemistry platform that combines AI with advanced physics-based tools to identify truly novel molecules that address unsolved challenges in drug discovery. The pipeline includes an oral STAT6 program with multiple novel scaffolds and an oral BRD4(BD2) program with the first truly selective inhibitor. DeepCure expects to start in clinical trials in 2026.
| Website | https://deepcure.com |
| Employees | 28 (18 on RocketReach) |
| Founded | 2018 |
| Address | 100 City Hall Plaza 5, Suite 502, Boston, Massachusetts 02108, US |
| Technologies |
JavaScript
,
HTML
,
Twitter
+28 more
(view full list)
|
| Industry | Biotechnology Research, Drug Discovery, Other Healthcare Technology Systems |
| Keywords | Immunology, Drug Discovery, Inflammatory Diseases, Drug Development, Immune System, Pharmaceutical, Biotechnology, Therapeutics, Molecular Discovery, Biopharma, Synthetic Chemistry, New Drugs, Precision Medicine, Clinical Trials |
| Competitors | Veeva Systems, Servier, Schrödinger, Recursion Pharmaceuticals, Insilico Medicine, Atomwise, Synthace, Cloud Pharmaceuticals, Inc., NuMedii, Allcyte +33 more (view full list) |
Looking for a particular DeepCure employee's phone or email?
Thrasyvoulos Karydis is the Co-Founder and CTO of DeepCure.
18 people are employed at DeepCure.
DeepCure is based in Boston, Massachusetts.